Prot #NU MSK22H05: Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)

Project: Research project

Project Details

StatusActive
Effective start/end date3/20/23 → 3/20/26

Funding

  • Memorial Sloan Kettering Cancer Center ((OE) Prot #NU MSK22H05 // (OE) Prot #NU MSK22H05)
  • BeiGene Ltd. ((OE) Prot #NU MSK22H05 // (OE) Prot #NU MSK22H05)